Brussels Conference On Innovation, Research and Competition In EU 12/05/2017 by Intellectual Property Watch 1 Comment An academic conference this month will explore issues related to innovation, research and competition in the European Union, addressing topics such as 5G, big data, patents and standards.
WHO, Stakeholders Take ‘First Step’ On Fair Pricing For Medicines 12/05/2017 by Catherine Saez and William New, Intellectual Property Watch 3 Comments The World Health Organization has concluded a major one-day forum on fair pricing of medicines, bringing a wide range of stakeholders together in Amsterdam and coming up with several possible actions for the way ahead. Key points of discussion included a definition of fair pricing, moving away from value-based pricing, delinkage of price from research and development costs, and greater transparency, according to participants.
WHO Touts Its Past Work On Improving Access To Medicines 11/05/2017 by Intellectual Property Watch Leave a Comment The World Health Organization today published an item entitled, Access to medicines: making market forces serve the poor, a chapter from its report ‘Ten years in public health 2007-2017’ of outgoing WHO Director General Margaret Chan.
WHO Studies On Local Pharma Production Provide Key Contrasts Between China, India 11/05/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment Two new studies published by the World Health Organization provide insight on the production of pharmaceutical products in India and China. According to the studies, China has a substantial local pharmaceutical manufacturing sector which the Chinese government is closely linking to its policy objective of universal health care. India, the main global provider of generic medicines is not pursuing a comparable focus on universal health care. India is increasingly faced with Chinese pharmaceutical sector competition, with China being its main provider of commoditized active pharmaceutical ingredients (APIs).
Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 by Tatum Anderson for Intellectual Property Watch 2 Comments The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars.
US, EU Diverge On Medical Diagnostic Patents 10/05/2017 by Kim Treanor for Intellectual Property Watch 1 Comment A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics.
MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 by Intellectual Property Watch 1 Comment The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines.
The True Believer: An Interview With New IFPMA Director General Thomas Cueni 08/05/2017 by Catherine Saez and William New, Intellectual Property Watch 2 Comments The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has long been at the centre of global public health policy in Geneva, representing industry from around the world. Now at a critical moment of change in the policymaking machinery, a new leader, Thomas Cueni of Switzerland, has taken over. Intellectual Property Watch recently sat down with him to discuss his views and vision going forward, and discovered his intellectual pragmatism and diverse experience which promise to open an ambitious new era for the association and global health policy.
Interplay Between Inter Partes Reviews (IPRs) And ITC Section 337 Proceedings 05/05/2017 by Guest contributor for Intellectual Property Watch Leave a Comment Since the passage of the America Invents Act (“AIA”) in 2011, Inter Partes Reviews (“IPRs”) before the Patent Trial and Appeal Board (“PTAB”) have assumed growing importance in patent litigation in federal district courts. Until recently, IPRs have not played a significant role in International Trade Commission (“ITC”) Section 337 investigations. While the ITC is unlikely to stay a Section 337 investigation, pending IPRs will likely have an increasing impact at the ITC, especially when an IPR proceeding reaches an advanced stage before or during the pendency of a Section 337 investigation. This article examines the limited interplay to date between IPRs and Section 337 proceedings and discusses potential implications for future investigations.
Paper: National Laws, UPOV, Should Be Revised To Ensure Farmers Rights 05/05/2017 by Intellectual Property Watch 1 Comment The right of farmers to use, exchange and sell farm-saved seeds should be ensured through national laws and a revision of the International Union for the Protection of New Varieties of Plants (UPOV), so the objectives of another United Nations international treaty on plant genetic resources can be fulfilled, a recent research paper states.